Grigg Ingham teamed up with Cree Gene to develop the next generation of breakthrough gene therapies

Today (January 18), Grigg Ingham and Suzhou Cree Gene Biotech Co., Ltd. (hereinafter referred to as Cree Gene) jointly announced that the two sides will adopt the exclusive VELP of Cree Gene. The platform develops new adeno-related virus (AAV) vectors for next-generation gene therapy.
This new collaboration combines Grigg Ingham's experience in disease mechanism research and gene therapy development with Cree Gene's expertise in virus library building and efficient in vivo AAV screening to provide patients with potentially safer and more efficient new AAV serotypes.
clinical applications of existing AAV serotypes are limited by certain characteristics, such as low transductivity and tissue specificity, as well as high immunogenicity.
, finding new AAV serotonies to overcome these challenges is critical for most AAV-based gene therapy. founded in 2016,
Cree Gene is an innovative gene therapy company focused on the application and development of virus delivery systems and gene editing systems, dedicated to expanding the frontiers of gene therapy through its innovative technologies, with the world's leading AAV manufacturing capabilities.
compared to other traditional carrier engineering techniques, Krygen's proprietary VELP? The platform has several key methodo innovations, including a comprehensive strategy for building a library of granules with high diversity and effective ratios.
-optimized AAV production solutions ensure high correctness of genomic and shell pairings and world-class viral library production capacity.
the same time physiologically related animal models can ensure the quality of AAV vector screening and verification.
through this series of technical innovations and optimizations, VELP? The platform greatly shortens the process of finding the "right" AAV carrier.
The first time that a global pharmaceutical company has worked with a Chinese biotech company in the frontiers of AAV vector engineering," said Dr. Qiushi Li, Chief Operating Officer of Kerek Gene.
thanks to Grigg Ingeham for our VELP? With the recognition of the platform, the new AAV vector expands the scope of treatment and is the key to realize the potential of gene therapy, which is also the innovation focus of Cree gene.
we believe that developing next-generation gene therapies with visionary partners such as Grigg Ingham can improve the quality of life for more patients.
"Biological Exploration Source: Bio-Discovery Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Metz Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here